KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) EBT Margin (2016 - 2026)

Edwards Lifesciences has reported EBT Margin over the past 17 years, most recently at 5.76% for Q4 2025.

  • For Q4 2025, EBT Margin fell 2239.0% year-over-year to 5.76%; the TTM value through Dec 2025 reached 20.98%, down 748.0%, while the annual FY2025 figure was 20.98%, 748.0% down from the prior year.
  • EBT Margin for Q4 2025 was 5.76% at Edwards Lifesciences, down from 22.43% in the prior quarter.
  • Over five years, EBT Margin peaked at 49.17% in Q4 2022 and troughed at 5.76% in Q4 2025.
  • A 5-year average of 29.47% and a median of 29.79% in 2024 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: surged 5783bps in 2021 and later crashed -2239bps in 2025.
  • Year by year, EBT Margin stood at 28.3% in 2021, then soared by 74bps to 49.17% in 2022, then crashed by -41bps to 29.0% in 2023, then fell by -3bps to 28.15% in 2024, then plummeted by -80bps to 5.76% in 2025.
  • Business Quant data shows EBT Margin for EW at 5.76% in Q4 2025, 22.43% in Q3 2025, and 26.12% in Q2 2025.